Vaxcyte (PCVX) Current Deferred Revenue (2019 - 2020)
Vaxcyte (PCVX) reported Current Deferred Revenue of $14000.0 for Q4 2020, down 26.32% year-over-year from $19000.0 in Q1 2020, and down 48.15% quarter-over-quarter from $27000.0 in Q3 2020.
Vaxcyte (PCVX) Current Deferred Revenue (2019 - 2020) Analysis & Trends
Vaxcyte (PCVX) has 2 years of Current Deferred Revenue data on file, last reported at $14000.0 in Q4 2020.
- Current Deferred Revenue for Q4 2020 came in at $14000.0, down 26.32% year-over-year; the trailing twelve-month figure through Dec 2020 was $14000.0 (down 26.32% YoY), and the FY2020 annual result was $14000.0, down 26.32% from the prior year.
- Current Deferred Revenue fell to $14000.0 in Q4 2020 per PCVX's latest filing, from $27000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $27000.0 in Q3 2020 and troughed at $14000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Vaxcyte | 6.34 Bn | 6.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 14,000.00 |
| Sep 30, 2020 | 27,000.00 |
| Jun 30, 2020 | 25,000.00 |
| Dec 31, 2019 | 19,000.00 |